Abdo, Mustafa
Uddin, Mohib
Goldmann, Torsten
Marwitz, Sebastian
Bahmer, Thomas
Holz, Olaf
Kirsten, Anne-Marie
Trinkmann, Frederik
von Mutius, Erika
Kopp, Matthias
Hansen, Gesine
Rabe, Klaus F.
Watz, Henrik
Pedersen, Frauke
,
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (82DZL001A4)
Article History
Received: 25 January 2021
Accepted: 24 May 2021
First Online: 3 June 2021
Declarations
:
: The study is a part from the prospective longitudinal All Age Asthma Cohort (ALLIANCE). The study was approved by local ethics committee at Medical School Luebeck, Germany, and is registered at clinicaltrials.gov (pediatric arm: NCT02496468; adult arm: NCT02419274).
: Not applicable.
: Mustafa Abdo reports no conflict of interest. Mohib Uddin reports no conflict of interest. Torsten Goldmann reports no conflict of interest; Sebastian Marwitz reports no conflict of interest, Thomas Bahmer reports grants from BMBF: Unrestricted research grant for the German Center for Lung Research (DZL), during the conduct of the study; personal fees from AstraZeneca, personal fees from GlaxoSmithKline, personal fees from Novartis, and personal fees from Roche, outside the submitted work. Olaf Holz reports no conflict of interest; Anne-Marie Kirsten reports no conflict of interest. Frederik Trinkmann received travel support from Actelion, Berlin Chemie, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma and TEVA as well as speaker or consultation fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Novartis and Roche, Sanofi aventis, all outside the submitted work. Erika von Mutius reports personal fees from Pharmaventures, personal fees from OM Pharma S. A., personal fees from Springer-Verlag GmbH, personal fees from Elsevier GmbH and Elsevier Ltd., personal fees from Peptinnovate Ltd., personal fees from Turun Yliopisto, personal fees from Tampereen Yliopisto, personal fees from Helsingin Yliopisto, personal fees from European Respiratory Society, personal fees from Deutsche Pharmazeutische Gesellschaft e. V., personal fees from Massachusetts Medical Society, personal fees from Chinese University of Hongkong, personal fees from European Commission, personal fees from Böhringer Ingelheim International GmbH, personal fees from Universiteit Utrecht, Faculteit Diergeneeskunde, personal fees from Universität Salzburg, personal fees from Georg Thieme Verlag, personal fees from Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI), outside the submitted work; In addition, Dr. von Mutius has a patent LU101064 - Barn dust extract for the prevention and treatment of diseases pending, a patent EP2361632: Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders with royalties paid to ProtectImmun GmbH, a patent EP 1411977: Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases licensed to ProtectImmun GmbH, a patent number EP1637147: Stable dust extract for allergy protection licensed to ProtectImmun GmbH, and a patent EP 1964570: Pharmaceutical compound to protect against allergies and inflammatory diseases licensed to ProtectImmun GmbH. Matthias V. Kopp reports no conflict of interest, Gesine Hansen reports no conflict of interest. Klaus F. Rabe reports grants and personal fees from Boehringer Ingelheim and Astra Zeneca, personal fees from Novartis, Roche, Chiesi Pharmaceuticals, Regeneron, Sanofi and Berlin Chemie outside the submitted work. Henrik Watz reports no conflict of interest, Frauke Pedersen reports no conflict of interest.